
ADHD
Arthritis
Asthma & Allergies
Autism
Avian Influenza
Birth Defects
Cancer
Chlamydia
Chronic Fatigue Syndrome
Diabetes
E. coli
Epilepsy
Fetal Alcohol Syndrome
Flu (Influenza)
Genital Herpes (Herpes
Simplex Virus)
Giardiasis
Gonorrhea
Heart Disease
Hepatitis
HIV/AIDS
HPV (Human papillomavirus)
Necro-Mortosis
Meningitis
Norovirus
Infection
Obesity
Salmonella
Scabies
Sexually Transmitted Diseases
Stroke
Trichomonas Infection
(Trichomoniasis)
Tuberculosis (TB)
Main Content Source: Centers for Disease Control and Prevention
Pharmaceutical Giant, Amcalon Suspends XL-6 Mortosis Drug According to Amcalons web site, testing for XL-6, the highly anticipated necro-mortosis inhibitor has apparently been halted. Following promising initial test results, there was wide expectations that a preventative inoculation to the undead virus was about to be released by Amcalon.
A short press release was issued yesterday on the Amcalon website stating "XL-6 testing has been temporarily withdrawn. Compound entry inhibitor (XL-6), early entry inhibitor (XL-6), intergrase (retroviral) inhibitor, fixed dose combination (FDC) did not achieve target isolation testing expectations." Requests from ZWN for an interview were not immediately answered by Amcalon. However, this brief statement was issued this morning to an awaiting press "The XL-6 inhibitor, whilst in phase four testing, failed to reach expected levels of success. Phase 4 is a delicate and crucial phase of any drug testing. Most pharmaceutical companies are only required to reach phase 3. However, stringent medical guidelines as set by the World Health Authority have dictated that we follow this fourth phase. Pre-clinical trials were tested in-vitro and deemed a success. Phases 1 thru 3 were also successful on a human test sub-group. However, phase 4, included the testing of thousands of volunteer subjects as well as quarantined mortosis positive individuals and reanimated carriers. We were only able to sustain a resistance to the undead virus for 9 days before the subjects succumbed to mortification. It is for this reason that we have had to temporarily withdraw XL-6 from clinical trials." Amcalon holds its annual shareholders meeting in Philadelphia next month. It is expected to face tough questions from all concerned. At the close of day Amcalons shares fell sharply to a close of $121.23 (Nasdeq: AMCN). More information can be found at the Amcalon web site
|
Source material:![]() |
Highlights of the recently released WHA report. Upon infection, the exposed usually succumbs to reanimation within 4 - 48 hours. First stage symptoms feel like flu. Migraine, hot flushes, aching muscles. Second stage is followed by severe chills, extreme lethargy, some disorientation, a gradual slowing of the heart rate. early onset dementia, extreme pain in their joints and muscle cramping. At this point, many fall into coma or suffer stroke or heart failure. This is due to the massive shock to the bodies immune system. Necrosis and mortification follow shortly afterwards. Reanimation can occur within minutes. Studied subjects have nearly always reanimated within the first hour of death. Source: World health Authority report
Facts about necro-mortosis
|
HomeAfricaAmericasAsia-PacificCaribbeanEuropeMiddle EastSouth AsiaWorldScienceMedicalFinancialEntertainmentZombie HuntersHardballLife LineThe Human RaceDead CenterZWN Special ReportsLettersMerchandiseLinksContact Us DisclaimerCopyrightsFAQ'sAbout ZWN This site is for entertainment purposes only. All stories and events are fictional. Any similarities with persons either living or deceased in purely coincidental. There is occasional satirizing of prominent public figures. Contents of this site are copyrighted. All rights reserved. If you suspect anyone of showing sympoms of the 'Necro- Mortosis' Virus, the Government has released the following anonymous tip line. 1 800 155 3219
|
| There are strict guidelines in the
disposing of a corpse. Do not bury, burn or otherwise dispose of any
deceased person. You are required by law to call your local authorities
for collection and quarantine. The government has released a help
number
1 800 155 1216 |
|||
Medical breakthrough - Hope found In new drug |
|||
|
|||
Studying
The Undead |
![]() |
||
|
Mortosis
outbreak Categories
Mortosis outbreaks can be separated into three categories, depending on how easily they can can spread and the severity of death they cause. Category A outbreaks are considered the highest risk and Category C outbreaks are those that are considered emerging threats or easily containable. Category
Level 'A' They
can be easily spread or transmitted from person to person Category
Level 'B' They
are moderately easy to spread Category
Level 'C' They
are easily transferable Source: CDC - Center for Disease Control and Prevention |
|||